SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Talpaz M,Kantarjian HM,McCredie KB,Keating MJ,Trujillo J,Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987; 69: 12801288.
  • 2
    Kantarjian HM,Smith TL,O'Brien S,Beran M,Pierce S,Talpaz M, and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α. Ann Intern Med. 1995; 122: 254261.
  • 3
    Kantarjian H,O'Brien S,Cortes J, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003; 97: 10331041.
  • 4
    Bonifazi F,de Vivo A,Rosti G, et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood. 2001; 98: 30743081.
  • 5
    Baccarani M,Saglio G,Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemianet. Blood. 2006; 108: 18091820.
  • 6
    O'Brien SG,Guilhot F,Larson RA, et al., for the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 9941004.
  • 7
    Druker BJ,Guilhot F,O'Brien SG, et al., IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 24082417.
  • 8
    Kantarjian H,Talpaz M,O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108: 18351840.
  • 9
    Kantarjian H,Cortes J,O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003; 101: 97100.
  • 10
    Kantarjian HM,Talpaz M,Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571: Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003; 9: 160166.
  • 11
    Hughes TP,Kaeda J,Branford S, et al., the International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 14231432.
  • 12
    Branford S,Seymour JF,Grigg A,Arthur C,Lynch K,Hughes T. Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up [abstract]. Blood. 2006; 108: 430.